SCHEMBL2283182

SCHEMBL2283182

Cc1noc(C)c1-c1c(C=O)c2cccc(F)c2n1-c1ccc(O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.42
LMNA P02545 2/20 0.38
BRD4 O60885 5/20 0.37
PIK3CD O00329 1/20 0.36
CYP1A2 P05177 3/20 0.34
CYP2C19 P33261 3/20 0.34
USP2 O75604 2/20 0.34
ALOX15 P16050 2/20 0.34
HSD17B10 Q99714 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
APEX1 P27695 1/20 0.34
ESR1 P03372 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
FTO Q9C0B1 1/20 0.33
CYP3A4 P08684 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
TSHR P16473 2/20 0.33
MAPK1 P28482 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2291718 0.88 CYP1A2 (0.35) ERN1LMNABRD4PIK3CDCYP1A2
SCHEMBL2291722 0.88 CYP1A2 (0.35) ERN1LMNABRD4PIK3CDCYP1A2
SCHEMBL2286133 0.85 ERN1 (0.48) ERN1LMNABRD4PIK3CDKMT2A
SCHEMBL13667933 0.84 PIK3CD (0.38) ERN1LMNABRD4PIK3CDCYP1A2
SCHEMBL2287848 0.84 ERN1 (0.44) ERN1LMNABRD4PIK3CDESR1
SCHEMBL2146131 0.83 ERN1 (0.41) ERN1LMNABRD4CYP1A2CYP2C19
SCHEMBL2146602 0.82 ERN1 (0.45) ERN1LMNABRD4PIK3CDESR1
SCHEMBL1076513 0.82 PIK3CD (0.36) LMNABRD4PIK3CDCYP1A2CYP2C19
SCHEMBL2285069 0.80 ERN1 (0.43) ERN1BRD4PIK3CDPTGDR2
SCHEMBL1076148 0.79 PIK3CD (0.35) LMNABRD4PIK3CDCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, GPER1 ERN1 384/4885LMNA 3473/4885BRD4 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.